Skip to main content

Table 1 Patient demographic, tumor, and treatment characteristics by race/ethnicity

From: Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: a prospective cohort study

Variable

Categories

Total

NHW

AA

HW

P 1

N

%

N

%

N

%

N

%

Total

 

366

100

58

16

73

20

235

64

 

Age (years)

< 50

95

26

18

31

19

26

58

25

0.613

≥ 50

271

74

40

69

54

74

177

75

 

Mean (SD)

56.0 (9.1)

55.6 (9.1)

54.9 (9.2)

56.5 (9.1)

 

BMI (kg/m2)

< 25

96

26

29

50

12

16

55

23

< 0.0001

25–29.9

124

34

16

28

17

23

91

39

 

≥ 30

146

40

13

22

44

60

89

38

 

Mean (SD)

29.3 (6.4)

26.6 (6.3)

32.6 (8.4)

28.9 (5.2)

 

Smoking status

Never

240

66

37

64

51

70

152

64

0.490

Former

107

29

20

34

17

23

70

30

 

Current

19

5

1

2

5

7

13

6

 

Sum of 12 comorbid conditions2

0

147

40

28

48

19

26

100

43

0.119

1

137

37

20

34

32

44

85

36

 

2

60

16

7

12

18

25

35

15

 

≥ 3

22

6

3

5

4

5

15

6

 

Tumor stage

0

74

20

7

12

14

19

53

23

0.003

IA-B

180

49

37

64

28

38

115

49

 

IIA-B

90

25

13

22

29

40

48

20

 

IIIA-C

22

6

1

2

2

3

19

8

 

ER

Positive

279

76

43

74

49

67

187

80

0.072

Negative

86

23

15

26

24

33

47

20

 

PR

Positive

243

66

36

62

44

60

163

69

0.243

Negative

122

33

22

38

29

40

71

30

 

HER2

Positive

31

8

4

7

6

8

21

9

0.730

Negative

275

75

50

86

56

77

169

72

 

Triple negative

No

294

80

47

81

52

71

195

83

0.005

Yes

54

15

8

14

20

27

26

11

 

Axillary surgery

None/SLNB

248

68

39

67

54

74

155

66

0.439

ALND

118

32

19

33

19

26

80

34

 

Chemotherapy

No

195

53

31

53

39

53

125

53

0.999

Yes

171

47

27

47

34

47

110

47

 

Hormone therapy/initiation time

None/after RT

178

49

37

64

41

56

100

43

0.015

Aromatase inhibitor before RT

98

27

9

16

14

19

75

32

 

Aromatase inhibitor during RT

14

4

3

5

2

3

9

4

 

Tamoxifen before RT

64

17

6

10

12

16

46

20

 

Tamoxifen during RT

12

3

3

5

4

5

5

2

 

RT fractionation

Conventional

306

84

45

78

64

88

197

84

0.298

Hypo

60

16

13

22

9

12

38

16

 

Total RT dose (Gy)

< 60

107

29

21

36

18

25

68

29

0.348

≥ 60

259

71

37

64

55

75

167

71

 

Mean (SD)

58.2 (4.8)

58.4 (4.6)

58.7 (4.9)

58.0 (4.8)

 

Boost

Yes

331

90

56

97

65

89

210

89

0.225

No

35

10

2

3

8

11

25

11

 

Breast volume (cc)

< 892.1 (median)

183

50

38

66

20

27

125

53

< 0.001

≥ 892.1 (median)

179

49

20

34

52

71

107

46

 

Mean (SD)

996 (532)

799 (464)

1254 (645)

965 (479)

 

Pre-RT pain

Mean (SD)

1.7 (2.1)

1.0 (1.3)

2.0 (2.5)

1.8 (2.1)

0.023

Post-RT pain

Mean (SD)

2.8 (2.5)

1.9 (1.7)

3.2 (2.6)

2.8 (2.6)

0.013

  1. 1P values from the chi-square test or Fisher's exact test, or ANOVA, excluding missing. Significant findings are in italics
  2. 2Sum of 12 patient-reported comorbid conditions: diabetes, hypertension, heart disease, lung disease, thyroid disease, cirrhosis liver, stroke, chronic bronchitis, hepatitis, tuberculosis, and 2 others
  3. Abbreviations: NHW non-Hispanic whites, AA black or African American, HW Hispanic whites, SD standard deviation, BMI body mass index, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, RT radiotherapy